Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
Sekeres MA, Tiu RV, Komrokji R, Lancet J, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J, Tabarroki A, Visconte V, Makishima H, Jerez A, Paquette R, List AF, Maciejewski JP. Sekeres MA, et al. Among authors: englehaupt r. Blood. 2012 Dec 13;120(25):4945-51. doi: 10.1182/blood-2012-06-434639. Epub 2012 Aug 22. Blood. 2012. PMID: 22915641 Free PMC article. Clinical Trial.
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA, Maciejewski JP, Erba HP, Afable M, Englehaupt R, Sobecks R, Advani A, Seel S, Chan J, Kalaycio ME. Sekeres MA, et al. Among authors: englehaupt r. Cancer. 2011 Mar 15;117(6):1253-61. doi: 10.1002/cncr.25686. Epub 2010 Oct 19. Cancer. 2011. PMID: 20960521 Free article. Clinical Trial.
Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.
Liu Y, Tabarroki A, Billings S, Visconte V, Rogers HJ, Hasrouni E, Englehaupt R, Kalaycio M, Sekeres MA, Saunthararajah Y, Tiu RV. Liu Y, et al. Among authors: englehaupt r. Leuk Lymphoma. 2014 Feb;55(2):447-9. doi: 10.3109/10428194.2013.802315. Epub 2013 Jun 24. Leuk Lymphoma. 2014. PMID: 23647061 No abstract available.
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
Saunthararajah Y, Sekeres M, Advani A, Mahfouz R, Durkin L, Radivoyevitch T, Englehaupt R, Juersivich J, Cooper K, Husseinzadeh H, Przychodzen B, Rump M, Hobson S, Earl M, Sobecks R, Dean R, Reu F, Tiu R, Hamilton B, Copelan E, Lichtin A, Hsi E, Kalaycio M, Maciejewski J. Saunthararajah Y, et al. Among authors: englehaupt r. J Clin Invest. 2015 Mar 2;125(3):1043-55. doi: 10.1172/JCI78789. Epub 2015 Jan 26. J Clin Invest. 2015. PMID: 25621498 Free PMC article. Clinical Trial.
Clinical experiences with ruxolitinib in symptomatic patients with myeloproliferative neoplasm with chronic kidney disease.
Tabarroki A, Visconte V, Rogers HJ, Sekeres MA, Samaras C, Lichtin A, Duong HK, Englehaupt R, Cinalli T, Dodd K, Desamito J, Rouphail B, Altman JK, Stein BL, Tiu RV. Tabarroki A, et al. Among authors: englehaupt r. Leuk Lymphoma. 2014 Jan;55(1):213-6. doi: 10.3109/10428194.2013.797086. Epub 2013 Jun 12. Leuk Lymphoma. 2014. PMID: 23607256 No abstract available.
A novel lunar bed rest analogue.
Cavanagh PR, Rice AJ, Licata AA, Kuklis MM, Novotny SC, Genc KO, Englehaupt RK, Hanson AM. Cavanagh PR, et al. Among authors: englehaupt rk. Aviat Space Environ Med. 2013 Nov;84(11):1191-5. doi: 10.3357/asem.3472.2013. Aviat Space Environ Med. 2013. PMID: 24279234